Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 3
2009 2
2010 4
2011 1
2012 1
2013 1
2014 1
2015 1
2017 1
2018 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme.
Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. Sandborn WJ, et al. Among authors: pulido rios mt. J Crohns Colitis. 2020 Sep 16;14(9):1202-1213. doi: 10.1093/ecco-jcc/jjaa049. J Crohns Colitis. 2020. PMID: 32161949 Free PMC article. Clinical Trial.
5-Hydroxytryptamine receptor assays.
Figueroa KW, Martin GR, Pulido-Rios MT. Figueroa KW, et al. Among authors: pulido rios mt. Curr Protoc Pharmacol. 2009 Sep;Chapter 4:Unit4.19. doi: 10.1002/0471141755.ph0419s46. Curr Protoc Pharmacol. 2009. PMID: 22294394
In vitro muscarinic receptor radioligand-binding assays.
Steinfeld T, Pulido-Rios MT, Armstrong S, Hegde SS. Steinfeld T, et al. Among authors: pulido rios mt. Curr Protoc Pharmacol. 2010 Mar;Chapter 1:Unit 1.33. doi: 10.1002/0471141755.ph0133s48. Curr Protoc Pharmacol. 2010. PMID: 22294363
In vitro isolated tissue functional muscarinic receptor assays.
Pulido-Rios MT, Steinfeld T, Armstrong S, Watson N, Choppin A, Eglen R, Hegde SS. Pulido-Rios MT, et al. Curr Protoc Pharmacol. 2010 Mar;Chapter 4:Unit 4.15. doi: 10.1002/0471141755.ph0415s48. Curr Protoc Pharmacol. 2010. PMID: 22294371
In vivo pharmacodynamic assays for M2 and M3 muscarinic receptors.
Armstrong S, Steinfeld T, Pulido-Rios MT, Hegde SS. Armstrong S, et al. Among authors: pulido rios mt. Curr Protoc Pharmacol. 2010 Mar;Chapter 12:Unit 12.13. doi: 10.1002/0471141755.ph1213s48. Curr Protoc Pharmacol. 2010. PMID: 22294364
Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.
Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR. Hegde SS, et al. Among authors: pulido rios mt. Pharmacol Res Perspect. 2018 Apr 30;6(3):e00400. doi: 10.1002/prp2.400. eCollection 2018 Jun. Pharmacol Res Perspect. 2018. PMID: 29736245 Free PMC article.
16 results